vs
Beam Therapeutics Inc.（BEAM）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
Beam Therapeutics Inc.的季度营收约是REGIS CORP的2.0倍（$114.1M vs $57.1M），Beam Therapeutics Inc.净利率更高（214.1% vs 0.8%，领先213.3%），Beam Therapeutics Inc.同比增速更快（279.5% vs 22.3%），REGIS CORP自由现金流更多（$891.0K vs $-87.0M）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
BEAM vs RGS — 直观对比
营收规模更大
BEAM
是对方的2.0倍
$57.1M
营收增速更快
BEAM
高出257.3%
22.3%
净利率更高
BEAM
高出213.3%
0.8%
自由现金流更多
RGS
多$87.9M
$-87.0M
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $57.1M |
| 净利润 | $244.3M | $456.0K |
| 毛利率 | — | — |
| 营业利润率 | -15.3% | 10.8% |
| 净利率 | 214.1% | 0.8% |
| 营收同比 | 279.5% | 22.3% |
| 净利润同比 | 370.4% | -94.0% |
| 每股收益（稀释后） | $2.53 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMRGS
| Q4 25 | $114.1M | $57.1M | ||
| Q3 25 | — | $59.0M | ||
| Q2 25 | — | $60.4M | ||
| Q1 25 | — | $57.0M | ||
| Q4 24 | — | $46.7M | ||
| Q3 24 | — | $46.1M | ||
| Q2 24 | — | $49.4M | ||
| Q1 24 | — | $49.2M |
净利润BEAMRGS
| Q4 25 | $244.3M | $456.0K | ||
| Q3 25 | — | $1.4M | ||
| Q2 25 | — | $116.5M | ||
| Q1 25 | — | $250.0K | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | — | $-853.0K | ||
| Q2 24 | — | $91.2M | ||
| Q1 24 | — | $-2.3M |
营业利润率BEAMRGS
| Q4 25 | -15.3% | 10.8% | ||
| Q3 25 | — | 10.0% | ||
| Q2 25 | — | 12.1% | ||
| Q1 25 | — | 8.8% | ||
| Q4 24 | — | 11.8% | ||
| Q3 24 | — | 4.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 8.3% |
净利率BEAMRGS
| Q4 25 | 214.1% | 0.8% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | 192.9% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 16.4% | ||
| Q3 24 | — | -1.9% | ||
| Q2 24 | — | 184.7% | ||
| Q1 24 | — | -4.7% |
每股收益（稀释后）BEAMRGS
| Q4 25 | $2.53 | $0.16 | ||
| Q3 25 | — | $0.49 | ||
| Q2 25 | — | $43.67 | ||
| Q1 25 | — | $0.08 | ||
| Q4 24 | — | $2.71 | ||
| Q3 24 | — | $-0.36 | ||
| Q2 24 | — | $38.40 | ||
| Q1 24 | — | $-1.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $18.4M |
| 总债务越低越好 | — | $113.3M |
| 股东权益账面价值 | $1.2B | $188.7M |
| 总资产 | $1.5B | $588.3M |
| 负债/权益比越低杠杆越低 | — | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资BEAMRGS
| Q4 25 | $1.2B | $18.4M | ||
| Q3 25 | — | $16.6M | ||
| Q2 25 | — | $17.0M | ||
| Q1 25 | — | $13.3M | ||
| Q4 24 | — | $10.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $5.9M |
总债务BEAMRGS
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
股东权益BEAMRGS
| Q4 25 | $1.2B | $188.7M | ||
| Q3 25 | — | $187.6M | ||
| Q2 25 | — | $185.6M | ||
| Q1 25 | — | $68.6M | ||
| Q4 24 | — | $66.7M | ||
| Q3 24 | — | $56.4M | ||
| Q2 24 | — | $56.8M | ||
| Q1 24 | — | $-35.8M |
总资产BEAMRGS
| Q4 25 | $1.5B | $588.3M | ||
| Q3 25 | — | $592.1M | ||
| Q2 25 | — | $599.0M | ||
| Q1 25 | — | $511.2M | ||
| Q4 24 | — | $530.1M | ||
| Q3 24 | — | $508.9M | ||
| Q2 24 | — | $530.5M | ||
| Q1 24 | — | $543.7M |
负债/权益比BEAMRGS
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | $1.7M |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | $891.0K |
| 自由现金流率自由现金流/营收 | -76.3% | 1.6% |
| 资本支出强度资本支出/营收 | 3.3% | 1.4% |
| 现金转化率经营现金流/净利润 | -0.34× | 3.65× |
| 过去12个月自由现金流最近4个季度 | — | $14.9M |
8季度趋势，按日历期对齐
经营现金流BEAMRGS
| Q4 25 | $-83.3M | $1.7M | ||
| Q3 25 | — | $2.3M | ||
| Q2 25 | — | $6.8M | ||
| Q1 25 | — | $6.2M | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | — | $-1.3M | ||
| Q2 24 | — | $5.1M | ||
| Q1 24 | — | $-277.0K |
自由现金流BEAMRGS
| Q4 25 | $-87.0M | $891.0K | ||
| Q3 25 | — | $1.9M | ||
| Q2 25 | — | $6.2M | ||
| Q1 25 | — | $5.9M | ||
| Q4 24 | — | $1.7M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $5.1M | ||
| Q1 24 | — | $-326.0K |
自由现金流率BEAMRGS
| Q4 25 | -76.3% | 1.6% | ||
| Q3 25 | — | 3.2% | ||
| Q2 25 | — | 10.3% | ||
| Q1 25 | — | 10.3% | ||
| Q4 24 | — | 3.6% | ||
| Q3 24 | — | -3.0% | ||
| Q2 24 | — | 10.3% | ||
| Q1 24 | — | -0.7% |
资本支出强度BEAMRGS
| Q4 25 | 3.3% | 1.4% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.1% |
现金转化率BEAMRGS
| Q4 25 | -0.34× | 3.65× | ||
| Q3 25 | — | 1.68× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
